Suzhou Senfeng Medical Completes Tens of Millions RMB Series A Funding to Advance Innovative Antimicrobial and Biodegradable Implantable Devices

VCBeat (WeChat ID: vcbeat) has learned that on September 30, 2021, Suzhou Senfeng Medical Instrument Co., Ltd., a pioneer in bulk antibacterial metal materials for implants (hereinafter referred to as "Senfeng Medical"), announced the completion of its Series A financing round, raising tens of millions of RMB.

This round of financing was led by Yuanhe Holdings, with participation from the SIP Science and Technology Innovation Fund, Qirong Venture Capital, and GF Qianhe. The funds will be used for the clinical trials and production capacity expansion of Senfeng Medical's core product, the inherently antibacterial orthopedic implant.

In August 2019, Prof. Yang Ke, a renowned expert in China's medical metal materials field, and Academician Dai Kerong, a distinguished clinical expert in orthopedics, jointly founded Senfeng Medical, which is dedicated to applying innovative medical metal materials to develop high-end medical devices primarily for orthopedics.

Currently, the industrial-scale production of intrinsic antibacterial metals and biodegradable magnesium alloys has been completed. The antibacterial titanium alloy orthopedic trauma product series is rapidly advancing through registration in the EU and China, with clinical trials scheduled to commence within this year. Furthermore, the vascular suturing device developed by the company has obtained EU CE certification and is currently undergoing registration in China.

Professor Yang Ke, Founder and Chairman of Senfeng MedicalStated: We are profoundly honored to receive the recognition and support from industry-leading investment institutions. The Senfeng team stands at the forefront of global research on novel medical metal materials. In recent years, we have pioneered the international development of various novel medical metal materials primarily characterized by their biological functionalities, creating new opportunities for the innovative advancement of metal-based medical devices. Empowered by capital markets and leveraging Senfeng Medical as our application platform for innovative medical metal materials, we will swiftly develop a portfolio of novel medical device products with strong international competitiveness, thereby generating substantial economic and social benefits.

Academician Dai Kerong, Founder of Senfeng MedicalStatement: In addition to sufficient strength and stiffness, artificial prostheses and internal fixation devices used for the treatment of bone and joint trauma and diseases should ideally possess excellent antimicrobial properties. Certain internal fixation products would optimally be bioresorbable, naturally degrading after the injury or condition has healed, thereby eliminating the pain and costs associated with a secondary removal surgery. It is hoped that the novel materials and implants developed in recent years through medical-engineering collaboration will meet these requirements and be rapidly translated into production and clinical application to benefit patients.

Project Director, Oriza HoldingsStatement: Based on two independently developed novel medical metal materials—bulk antibacterial metal and biodegradable magnesium alloy—Senfeng Medical has developed orthopedic implant products featuring innovative biological functions. The company is poised to be the first in China to launch antibacterial titanium alloy orthopedic devices, which are designed to prevent postoperative infections following orthopedic implantation. Meanwhile, its biodegradable magnesium alloy orthopedic devices can eliminate the need for secondary surgical removal of certain orthopedic implants. We look forward to Senfeng Medical's products entering clinical practice soon to benefit a broad patient population.

Project Director, Lingjun Venture Capital (GP of the Suzhou Industrial Park Sci-Tech Innovation Fund)Stated: Senfeng Medical is a major science and technology leading project in Suzhou Industrial Park, and also one of the first enterprises to sign agreements with the park's Sci-Tech Innovation Fund. The project brings together top domestic experts in biomedical materials and orthopedic clinical specialists, focusing on the development and industrialization of orthopedic implant products and innovative medical materials. All orthopedic implant products developed by the company feature innovative biological functions that effectively address key challenges in clinical applications, benefiting patients and society. Meanwhile, innovative medical materials constitute a critically important segment of the implantable and interventional medical device industry chain. The investment in Senfeng Medical is also aimed at further developing and optimizing the park's ecosystem for implantable and interventional medical devices, thereby enhancing regional innovation capabilities.

Yu Yongping, General Manager of Qirong CapitalStated: Competition in China's traditional orthopedic device industry is becoming increasingly intense, and companies must establish unique competitive advantages through original innovation to stand out. Senfeng Medical has assembled top experts in the fields of materials and orthopedic devices, particularly accumulating profound technical expertise in orthopedic biomaterials, which has forged its distinctive characteristics. In the domain of intrinsic antibacterial materials and devices, Senfeng has taken a leading position in the industry, and we are highly optimistic about the company's development prospects. We hope Senfeng Medical's products can be advanced to clinical applications as soon as possible to benefit patients; meanwhile, we also hope to continuously support Senfeng's growth.

Hu Jin, General Manager of the Healthcare Investment Department at GF QianheStated: Senfeng Medical possesses intrinsic antibacterial metal material technology, which can be widely applied to orthopedic implant medical devices. It is expected to effectively prevent bacterial infections potentially associated with orthopedic implant surgeries, featuring industry-leading innovative attributes and significant clinical value, with broad market prospects. GF Qianhe is highly optimistic about the company’s original innovations at the upstream raw material level and its commitment to developing orthopedic implants with antibacterial properties. We are deeply honored to grow alongside the company and contribute more substantially to the advancement of innovative medical devices in China!